This Breakout Healthcare Growth Stock Is Too Cheap to Miss
Before the pandemic, Fulgent Genetics (NASDAQ: FLGT) was a little-known genetic testing business with grand ambitions but limited means. Since January of 2020, its stock has provided the not-too-shabby return of 385%.
Now, with more than $1 billion in trailing 12-month revenue derived mainly from sales of its coronavirus diagnostics and a wildly successful two years in the rearview mirror, it stands ready to thrill its investors once again.
Though it's unlikely to replicate the same impressive performance between now and 2024, there's still reason to believe that the stars are aligning in its favor. Let's take a brief walk through Fulgent Genetics' business and the inexpensive valuation of its shares to see if it might be a good fit for your portfolio in 2022.
Source Fool.com
